Genomic libraries of Mycobacterium leprae DNA partially digested with Pst I were constructed in the expression vector pYA626, which contains the promoter region from the Streptococcus mutans gene encoding aspartate asemialdehyde dehydrogenase, which is very efficiently expressed in Escherichia coli. We have detected several clones that complement a mutation in the citrate synthase gene of E. coli. Southern blot analysis demonstrated that the complementing DNA was M. leprae DNA. Sodium dodecyl sulfate/polyacrylamide gel analysis of polypeptides produced by minicells containing the citrate synthase-complementing recombinant molecules demonstrated the production of a 46-kDa polypeptide. When the citrate synthase-complementing fragment was cloned in pYA626 in the reverse orientation, the recombinant molecule was no longer able to complement the mutation in the citrate synthase gene and no longer produced the 46-kDa polypeptide. When the DNA fragment was cloned in the Pst I site of pHC79, so as to allow expression from the (3-lactamase promoter, the resulting recombinant failed to complement the mutation in the E. coli citrate synthase gene yet still produced the 46-kDa polypeptide, but in one-fourth the amounts than when expressed from the S. mutans asd promoter. This demonstrates that M. leprae translational sequences can be recognized by E. coli translational machinery. Promoter expression vectors can be used to obtain expression of protein antigens to be used for early diagnosis of leprosy or components of a vaccine and proteins that are targets of potential antileprosy drugs.
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Leprosy, an age-old chronic disease with a wide spectrum of manifestations, including gross skin disfigurement and peripheral nerve loss, afflicts over 15 million people in the world today (1) . Its causative agent, Mycobacterium leprae, was shown to be associated with the disease by Gerhard Armauer Hansen in the early 1870s (2) . Even so, M. leprae has been extremely difficult to study because of its inability to be cultivated in the laboratory. In the early 1960s, Shepard successfully cultivated M. leprae in the footpads of mice (3) . Significant quantities of the organism became available for research upon the discovery that M. leprae produced a systemic infection in the nine-banded armadillo, Dasypus novemcinctus (4, 5) .
We had previously screened genomic libraries ofM. leprae DNA cloned in both plasmid and cosmid vectors and had not observed any complementation of a variety of mutations in amino acid, purine, and vitamin biosynthetic pathways or carbohydrate catabolic pathways in Escherichia coli K-12 (6) . We cloned M. leprae DNA in the expression vector pYA626 and were able to demonstrate the expression of M. leprae polypeptides in minicells containing recombinant M. leprae molecules (6) . In this manuscript, we describe the complementation of a mutation in the citrate synthase (EC 4.1.3.7) gene of E. coli K-12 by cloned M. leprae DNA that is expressed from the asd promoter of pYA626.
MATERIALS AND METHODS
Bacterial Strains and Methods. Table 1 lists and describes the E. coli strains used in this study. Phage P1 transduction (11) , cosmid transduction (6), and transformation (12) were performed as described previously.
Media. E. coli strains were grown in L broth (13) supplemented with diaminopimelic acid and thymidine, if necessary, or minimal salts broth or agar supplemented with amino acids, nucleotides, vitamins, and glucose (11) . L-Glutamic acid was sterilized by filtration.
Preparation of DNA. M. leprae, Mycobacterium vaccae, Mycobacterium "lufu," and D. novemcinctus (nine-banded armadillo) DNAs were isolated and purified as described previously (6) . Plasmid DNA was extracted by the Birnboim technique (14) with subsequent purification by centrifugation on cesium chloride/ethidium bromide density gradients, if necessary. DNAs were analyzed on 0.7% agarose gels (ref. 15 and that of the aroB mutation, at a frequency of i0-7. We did not observe complementation of any of the other mutations in this screening. Retransformation of X2338 with plasmids isolated from clones selected for their ability to grow on minimal medium lacking glutamate in the presence of tetracycline showed 100% cotransformation of tetracycline resistance and the gltA-complementing activity. The clones that complemented the gitA mutation were able to form colonies 0.5-1.0 mm in diameter on minimal medium lacking glutamate and containing tetracycline after 4 days of growth at 370C. Similar results were obtained when the clones were grown at 30'C. On minimal medium containing glutamate and tetracycline, X2338 harboring pYA1036 (the recombinant molecule complementing the citrate synthase gene from the 3-kb library) formed colonies of similar size after 36-48 hr of incubation at 30'C or 370C. An isogenic gltA' derivative of X2338 also formed colonies 0.5-1.0 mm in diameter after 36-48 hr of incubation at 30'C or 370C.
Digestion of pYA1036 by the restriction endonuclease Pst I followed by agarose gel electrophoresis revealed a single 2.6-kb insert in pYA626 (Fig. 1, lane 1) . The gitA-complementing recombinant molecule found in the 6-kb library (pYA1037) also contained a 2.6-kb Pst I fragment, plus four additional small Pst I fragments (Fig. 1, lane 2) . The presence of identically sized BamHI and EcoRV-Xho I fragments in both pYA1036 and pYA1037 showed that the position and orientation of the common 2.6-kb fragment was identical with respect to the asd promoter in the two plasmids (Fig. 1) . We screened the previously described pHC79::M. Ieprae DNA cosmid libraries (6) in x2819 for the presence of sequences that hybridize with the 2.6-kb gltA-complementing fragment by colony hybridization. Strong hybridization with 20 out of 1600 colonies was observed, thus confirming the presence of the gitA-complementing fragment in our original libraries, although we had not observed complementation of the gitA mutation in X2338, probably because the M. Ieprae promoter for this gene does not function well in E. coli.
Expression of the gltA-Complementing Activity. To test whether the gltA-complementing activity was being expressed from the asd promoter of pYA626 or from its own promoter, we recloned the 2.6-kb gltA-complementing fragment in pYA626 and then screened for recombinant molecules containing the fragment in either orientation with respect to the asd promoter. The recombinant molecule pYA1040, which had the 2.6-kb fragment in the same orientation as in pYA1036, was able to complement the gltA16 mutation in X2338. However, when the 2.6-kb insert was cloned in the opposite orientation with respect to the asd promoter to yield pYA1041, no complementation of the mutation in the citrate synthase gene was observed (Fig. 3) .
To determine what polypeptides were being synthesized by the cloned DNA, radiolabeled polypeptides produced in minicells containing various recombinant plasmids were analyzed. The vector, pYA626, specified the production of a 14-kDa fusion polypeptide consisting of the amino terminus of aspartate P-semialdehyde dehydrogenase and the carboxyl terminus of f3-lactamase, as well as the 34-kDa tetracyclineresistance gene product (Fig. 4, lane 2) . The two original gltA-complementing clones (pYA1036 and pYA1037) as well as the reconstructed gltA-complementing clone (pYA1040) all produce a unique polypeptide of 46 kDa that is not produced in minicells containing pYA1041 (Fig. 4, lanes 3, 4 , 5, and 6). In fact, pYA1041 specifies the production of two different polypeptides of 14 and 25 kDa (Fig. 4, lane 5) . Neither of these polypeptides is specified by any of the gltA-complementing recombinant molecules.
To tide was a fusion polypeptide with the amino terminus of the aspartate P-semialdehyde dehydrogenase, the 2.6-kb Pst I fragment was inserted into the Pst I site of pHC79, a small (6-kb) cosmid vector in which the f3-lactamase promoter is located upstream from the Pst I site (16) . Recombinant molecules containing the 2.6-kb insert in either orientation with respect to the f3-lactamase promoter were analyzed. Neither pYA1044 (same orientation of the 2.6-kb insert as in the gltA-complementing molecules with respect to the f3-lactamase promoter) nor pYA1045 was able to complement the gitA mutation in X2338 (Fig. 3) . Ifthe gltA-complementing polypeptide was fused with the 41-residue amino terminus of the asd gene product, it should also form a fusion polypeptide with the 159-residue amino terminus of P-lactamase in pHC79
and produce a much larger fusion polypeptide (17) . Both pYA1036 and pYA1044 specified the production of a 46-kDa polypeptide (Fig. 5, lanes 3 and 5) . However, four times more of the 46-kDa protein was produced from the asd promoter than from the ,B-lactamase promoter when normalized to the 34-kDa tetracycline-resistance gene product. 1036. Growth rates were determined for W620, K2-1-4, and X2338. which contain three different mutations in the citrate synthase gene ofE. colU (the gltA6, gitA9, and gltA16 alleles), with and without pYA1036 in liquid minimal media with concentrations of L-glutamic acid varying from 10 to 200 ,g/ml. X2338 failed to grow in the absence of glutamate, whereas X2338 containing pYA1036 in Mhinimal media without glutamate reached an optical density one-sixth the level of cultures of X2338 containing 200 ,ug/ml or cultures of an isogenic gltA+ strain after 48 hr ofgrowth at 37°C. In repeated experiments with media containing 10 or 25 A~g of glutanmate per ml, cultures ofX2338 containing pYA1036 always reached optical densities that were 15 to 20 times higher than the plasmidless strain. In similar experiments using the gitA6 and gitA9 mutant strains with and without pYA1036, both strains failed to grow in liquid minimal media that lacked glutamate, even when they contained pYA1036. However, in repeated experiments, cultures of these strains harboring pYA1036 grew to densities that were 0.3 to 9 times higher than the plasmidless derivatives in media containing 10 or 25 ug of glutamate per ml. Thus, the cloned M. Ieprae gene partially complements the gitA6 and gltA9 mutations in these E. coli host strains.
Spontaneous reversion frequencies for the three gitA mutations were as follows: gitA6, <7.5 x 10-1"; gitA9, <4 x 10-11; and gitA16, <5 x 10-1". effect on the reversion frequencies of any of these alleles. Therefore, the ability of X2338 possessing pYA1036 to grow in minimal media lacking glutamate or with suboptimal concentrations of glutamate must be due to the presence of a functional citrate synthase on the cloned fragment. Stability of the gltA-Complementing Polypeptide. The Ion gene specifies a protease that degrades abnormal proteins (18) , including fusions of f-galactosidase with foreign gene products (19) . However, pulse-chase analyses of the gltAcomplementing polypeptide produced in minicells from two isogenic E. coil strains differing only inrthe presence of lon+ or lon-9 alleles revealed no difference in the rates of degradation of the M. leprae protein in these two strains (data not shown).
DISCUSSION
The results demonstrate the expression of an M. leprae gene that partially complements mutations in three different alleles of the citrate synthase gene in E. coli K-12 when cloned in the proper orientation downstream from the very efficient S. mutans asd promoter. The complementing DNA fragment specifies a 46-kDa polypeptide when expressed from both the ,B-lactamase of pHC79 and the asd promoter of pYA626. Thus, the 46-kDa M. leprae gene product is not a fusion polypeptide with the amino terminus of either /lactamase or aspartate /3-semialdehyde dehydrogenase. Therefore, the M. leprae translational initiation signal for this gene is recognized by E. coli translational machinery.
Failure to observe complementation of the citrate synthase mutation by the cloned M. Ieprae gene when the gene is expressed from the &3lactamase promoter, which resulted in a production of the 46-kDa polypeptide of one-fourth compared to when the M. leprae gene was expressed from the asd promoter, indicates that decreased activity due to a lower level of expression precludes complementation on solid or in liquid minimal media. Even expression of the 46-kDa polypeptide from the asd promoter is insufficient for growth of X2338 to the level of an isogenic gltA' strain. The observations that the presence of the recombinant plasmid, pYA1036, in strains W620 (which contains the gltA6 allele) and K2-1-4 (which contains the gltA9 allele) is inadequate to support growth of those strains in the absence of glutamate, yet enhances the growth of the strains in media containing suboptimal concentrations ofglutamate suggest that the level of activity of the complementing gene product is a result of lower expression in these two strains. Alternatively, since W620 and K2-1-4 have shorter generation times than X2338, they may require greater citrate synthase activity per unit time to sustain their growth.
A mutation in the citrate synthase gene of E. coli results in auxotrophy for the glutamate family of amino acids (20, 21) . Since the presence of the cloned M. leprae gene enhances the growth ofthree E. coti strains with three different gitA alleles, this strongly suggests that the cloned gene product is citrate synthase. The citrate synthase gene of Rickettsia prowazekii was identified by its ability to complement the gltA6 allele (22) . The gltA16 allele has been mapped by P1 transduction to the known site of the citrate synthase gene, and strains possessing the gltA16 have been shown to be devoid of citrate synthase activity (unpublished results). Wheeler has demonstrated low citrate synthase activity in extracts of M. leprae cells grown in armadillos, although high levels of oxaloacetate were required for in vitro activity of the M. leprae citrate synthase (23) . This result suggests that the M. leprae enzyme is different from the E. coli citrate synthase and could account for low in vivo activity in the recombinant clones. The molecular weight of the cloned M. leprae gene product is 46,000, determined by NaDodSO4/polyacrylamide gel electrophoresis (PAGE). This is very similar to the molecular weight of the cloned E. coli citrate synthase, which was also determined to be 46,000 by NaDodSO4/PAGE (24) , although the predicted molecular weight of the E. coli citrate synthase inferred from the DNA sequence is 48,069 (25) . The molecular weight of the M. leprae citrate synthase from M. leprae cell extracts has not yet been determined.
The demonstration of the presence of the citrate synthasecomplementing sequence in cosmid clones that were unable to complement the citrate synthase mutation and the inability to detect complementation of nine other auxotrophic mutations in E. coli host strains by recombinant cosmid molecules (ref. 6; this paper) imply that M. leprae promoters are not expressed or are very inefficiently expressed in E. coli. On the basis of the low level of expression of the 46-kDa polypeptide in minicells containing pYA1036 compared to the level of expression of the asd-,B-lactamase fusion polypeptide (Fig. 5, lanes 2 and 3) , it would appear that initiation of translation of the M. leprae citrate synthase gene is much less efficient than translation initiation of the asd-(-lactamase fusion polypeptide. In this regard, the Shine-Dalgarno sequence of the asd promoter has 8 of 9 bases complementary to the 3' end of the 16S ribosomal RNA of E. coli (G. Cardineau and R.C., unpublished data). Thus, expression of other myc6bacterial genes may be enhanced by constructing protein or operon fusions. We have inserted a DNA sequence with multiple cloning sites downstream from the asd promoter in both plasmid and X vectors to facilitate such constructions.
The ability to express M. leprqe genes in E. coli by using promoter expression vectors will provide many new opportunities to understand M. leprae and the disease of leprosy. Expression of protein antigens of M. leprae should permit identification of those entities that are important for protective immunity against leprosy and ultimately provide a source of material for a possible vaccine. Young et al. have recently identified several polypeptide antigens by screening a Xgtll::M. leprae library with monoclonal antibodies directed against specific M. leprae antigens (26) . The ability to complement a mutation in E. coli demonstrates that a functional M. leprae enzyme has been expressed. Expression of other M. leprae enzymes that are putative targets of anti-leprosy drugs will provide material to screen the potential effectiveness of such drugs in E. coli in lieu of costly screening in mouse footpad assays (27) and will facilitate analysis of mechanisms of action of such drugs.
